KRAS G12C lung cancer: targeted medicines and where glecirasib fits

Check that the mutation is G12C

KRAS is a gene involved in growth signaling. G12C describes one particular alteration. Other KRAS variants, such as G12D or G12V, are different targets and should not be treated with a G12C inhibitor solely because KRAS appears on the report.

Ask the oncologist to identify the exact variant and the sample used for testing. A broad molecular panel may also report other findings that affect the interpretation. Keep the complete report so a second team can see both the result and the laboratory's assessment of sample quality.

Sources and references: [1] [2]

Why initial treatment may still include immunotherapy

The presence of KRAS G12C does not automatically place a targeted tablet ahead of every other first-line option. In advanced NSCLC, histology, PD-L1, disease burden and general health help determine the initial systemic regimen. Immunotherapy with or without chemotherapy can remain part of that discussion.

Ask whether the proposed treatment is intended for previously untreated disease or after progression. This distinction is particularly useful when online accounts compare patients at very different points in their illness. A treatment sequence needs evidence for each step.

Sources and references: [1]

Understand the role of later-line inhibitors

Sotorasib and adagrasib are examples of KRAS G12C inhibitors used in defined previously treated NSCLC settings. A clinician compares them with other systemic options according to prior treatment, health conditions and the local prescribing framework.

Oral administration can make the schedule more convenient, but it still involves regular monitoring. Ask about liver tests, gastrointestinal effects, interactions and how response will be assessed. If you previously received immunotherapy, include its name and last dose in the treatment history so the next team can plan safely.

Sources and references: [1] [3]

Glecirasib's relevant China indication

Glecirasib, also called JAB-21822, is a KRAS G12C inhibitor. China approved glecirasib in May 2025 for KRAS G12C-mutated NSCLC after at least one prior systemic therapy. That gives patients a specific later-line option to discuss with a Chinese oncology team.

Its published phase 2b study evaluated single-agent treatment in advanced KRAS G12C-mutated NSCLC. When comparing glecirasib with another inhibitor, ask how closely the study patients match your previous treatment, current disease and health. The team can use the response and safety findings to explain which option fits your situation.

Sources and references: [4] [5]

Ask how a research combination would fit your treatment

Researchers are studying combinations intended to deepen responses or delay resistance, including glecirasib with the SHP2 inhibitor sitneprotafib. If this pair is proposed, ask which current trial or approved local indication supports the combination and whether your treatment history fits its requirements.

If a combination is proposed, ask for the trial identifier or the applicable local indication, the prior-treatment requirements and the expected monitoring. Also clarify whether you would receive the experimental regimen for certain or be randomized between study groups. These details affect both the medical decision and the practical schedule.

Sources and references: [4] [6]

A second inhibitor is not an automatic next step

After a KRAS G12C medicine stops working, cancer may have acquired resistance that also affects another drug in the same class. A change in symptoms or scans should prompt a review of the pattern of progression and the useful testing options.

The next route may involve chemotherapy, a clinical trial or selected local treatment. Ask what evidence supports another inhibitor in your actual sequence. Retesting is most useful when the team can explain how a finding would change treatment, rather than ordering a panel simply because a drug has failed.

Sources and references: [3] [1]

Plan for side effects early

KRAS-directed treatment can cause gastrointestinal and liver-related problems, with the exact profile varying by medicine. Report persistent diarrhea, difficulty keeping fluids down, yellowing of the skin or eyes, and new breathing symptoms promptly. Some problems are first detected through blood tests before you feel unwell.

Ask for written instructions on missed doses, food requirements and contact outside clinic hours. A treatment diary that includes supplements and recent medication changes can help the team identify an interaction. Dose changes should come from the prescribing team.

Sources and references: [3] [1]

Make the Shanghai question specific to your treatment line

If glecirasib or a trial is relevant to your inquiry, EastMedGo can help organize the KRAS report and prior-treatment timeline for a specialist appointment request. Include the best response and reason for stopping each regimen. The lung cancer page provides related Shanghai resources.

We can help clarify hospital assessment requirements and coordination charges. Ask the hospital to confirm the current indication, suitability and prescribing arrangements before making travel plans around a named drug. That turns the inquiry into a decision about a defined treatment step.

Common questions